

## ASX RELEASE

24 November 2015

### Results of Annual General Meeting

**MMJ PhytoTech Limited (ASX:MMJ)** ("MMJ" or the "Company") today held its Annual General Meeting at the Four Points Sheraton Hotel, 707 Wellington Street, Perth WA 6000.

All resolutions were passed on a show of hands.

In accordance with section 251AA of the Corporations Act, proxy votes exercisable by all proxies validly appointed were;

Resolution	For	Discretionary	Abstain	Against
1. Adoption of Remuneration Report	22,531,440	134,428	3,016,729	3,015,283
2. Re-election of Director – Peter Wall	25,558,447	3,114,428	Nil	25,005
3. Election of Director – Winton Willesee	25,558,447	3,114,428	Nil	25,005
4. Appointment of Auditor	25,566,723	3,114,428	16,729	Nil
5. Approval to Increase Maximum Aggregate Remuneration for Non-Executive Directors	15,704,295	114,428	9,610,961	3,268,196
6. Ratification of Issue of Fee Shares	25,410,710	3,114,428	1,000	171,742
7. Ratification of Placement of Shares and Options	25,436,381	3,114,428	1,000	146,071
8. Ratification of Issue of Fee Shares	25,319,156	3,114,428	51,000	213,296
9. Placement of Options to Advisers	25,381,822	3,114,428	50,000	151,630
10. Approval of 10% Placement Capacity	25,389,006	3,114,428	Nil	194,446

## ASX RELEASE

---

### For more information please contact

Erlyn Dale

Company Secretary

+61 8 9389 3150

[info@mmjphytotech.com.au](mailto:info@mmjphytotech.com.au)

### About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory.

**Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.

<http://www.mmjphytotech.com.au>